<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2007</study_start_year><condition></condition><condition>UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER</condition><disease></disease><disease>Unresectable Liver Metastases From Colorectal Cancer</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2522576</full_dataset_link><location>Italy</location><study_start_month>5</study_start_month><keyword>CAMPTO</keyword><keyword>AVASTIN</keyword><keyword>FLUOROURACILE TEVA</keyword><keyword>ELOXATIN</keyword><keyword>LEDERFOLIN</keyword><repository>ECRIN MDR</repository><study_status>Ongoing</study_status></additional><is_claimable>false</is_claimable><name>PHASE II TRIAL OF FOLFIRI REGIMEN PLUS BEVACIZUMAB ALTERNATED WITH OXALIPLATIN-BASED HEPATIC ARTERIAL INFUSION PLUS DE GRAMONT REGIMEN AND BEVACIZUMAB IN THE TREATMENT OF UNRESECTABLE LIVER METASTASES FROM COLORECTAL CANCER</name><description>Primary objectives: TUMOR RESPONSE RATE (RR)</description><dates><creation>2007-05-15</creation></dates><accession>2522576</accession><cross_references><EU Clinical Trials Register>2007-003484-45</EU Clinical Trials Register></cross_references></HashMap>